Other Issues

CHPA supports the regulatory authorities governing dietary supplement manufacturing, labeling, and marketing and works to ensure the availability of safe dietary supplements.

Save the date for upcoming CHPA meetings and events!

Imposing extended producer responsibility (EPR) laws on medical device makers would be an excessive regulation given that most major companies in the industry have already implemented voluntary programs for free consumer battery recycling.

CHPA is instrumental in shaping the policy and regulatory environment in the OTC medicine, dietary supplement, and OTC medical device industries.

Rather than create a patchwork of statutes across jurisdictions, lawmakers should allow the comprehensive standards established by national microplastics and microbead legislation to facilitate steady industry progress on materials and waste reduction guided by science.

Imposing Proposition 65 state-level requirements on chemicals actively regulated under federal purview risks duplicative warnings that undermine public trust in national safety determinations. Since the FDA derives allowable limits from the best available science, overriding federal risk-benefit guidelines with California-specific thresholds triggers unnecessary labeling not reflecting real-world exposures from routine product usage shown to be safe.

View members-only reports outlining progress on CHPA state legislative priorities.

This proposed safety administrative order addresses the GRASE status of OTC oral health care drug products containing benzocaine alone or with phenol preparations labeled for anesthetic/analgesic indications (21 CFR 356).